Abstract
While approval of the first potentially disease-modifying medication for Alzheimer's disease is promising, there are mixed opinions and many practical issues still need to be resolved.1 Advanced neuroimaging techniques have greatly enhanced early diagnosis of dementia. The Amyloid-Tau-Neurodegeneration framework for biomarker profiling of neurocognitive disorders attempted to shift the diagnostic paradigm from clinical syndromes to neuroimaging and biochemical evaluation of neurodegeneration, aiming towards identifying a presymptomatic phase of such diseases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
